Article
Gastroenterology & Hepatology
Juhan Lee, Jae Geun Lee, Shin Hwang, Kwang-Woong Lee, Jong Man Kim, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Hee Chul Yu, Geun Hong, Dongho Choi, Ju Ik Moon, Myoung Soo Kim
Summary: In liver transplant recipients, the use of TDF is associated with an increased risk of renal dysfunction compared to ETV. Older age, worse baseline renal function, and low body mass index are independent risk factors for renal dysfunction after liver transplantation. Patients with renal dysfunction have a significantly lower overall survival rate compared to those without.
HEPATOLOGY INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn, Seung Up Kim
Summary: The study compared the effects of three antiviral agents on the risk of hepatocellular carcinoma and orthotopic liver transplantation or mortality in patients with chronic hepatitis B. It was found that the outcomes of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide were statistically similar in treatment-naive patients with CHB.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Shao-Ming Chiu, Kuo-Chin Chang, Tsung-Hui Hu, Chao-Hung Hung, Jing-Houng Wang, Sheng-Nan Lu, Chien-Hung Chen
Summary: This study compared the one-year retreatment efficacy and renal safety of entecavir, TDF, and TAF in patients with HBV relapse. The results showed no significant difference in virological response and ALT normalization among the three groups after 12 months of retreatment. Lower baseline levels of HBV DNA and HBsAg were independently associated with virological response at 12 months of retreatment. The TDF group had higher ALT levels at 12 months of retreatment, while the eGFR increased in the entecavir and TAF groups.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Jonggi Choi, Chanyoung Jo, Young-Suk Lim
Summary: This study compared HCC recurrence and survival in HBV-related HCC patients treated with TDF or ETV after surgical resection, finding that TDF therapy was associated with a significantly lower risk of HCC recurrence and better overall survival.
Article
Gastroenterology & Hepatology
Deok-Gie Kim, Youngrok Choi, Jinsoo Rhu, Shin Hwang, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Bong-Wan Kim, Jai Young Cho, Koo Jeong Kang, Jae Do Yang, Donglak Choi, Dong Jin Joo, Myoung Soo Kim, Je Ho Ryu, Jae Geun Lee
Summary: This study compared the outcomes of ETV and TDF for HBV-related HCC patients after liver transplantation. The results showed similar survival rates and risks of HCC recurrence and overall death between the ETV and TDF groups. Neither ETV nor TDF showed superiority in different HCC characteristics and treatment situations.
LIVER TRANSPLANTATION
(2023)
Article
Infectious Diseases
Juan Li, Chunhua Hu, Yi Chen, Rou Zhang, Shan Fu, Mimi Zhou, Zhijie Gao, Mengjun Fu, Taotao Yan, Yuan Yang, Jianzhou Li, Jinfeng Liu, Tianyan Chen, Yingren Zhao, Yingli He
Summary: The study found that TAF, TDF, and ETV have similar efficacy and safety in the treatment of HBV-ACLF in both short-term and long-term treatment. TAF showed priority in reducing total bilirubin and maintaining albumin and cholesterol levels compared to the other two drugs.
BMC INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Junyi Shen, Weili Qi, Junlong Dai, Shusheng Leng, Kangyi Jiang, Yu Zhang, Shun Ran, Chuan Li, Tianfu Wen
Summary: This study compared the effects of tenofovir (TDF) and entecavir (ETV) on the recurrence of hepatocellular carcinoma (HCC) beyond the Milan criteria. The results showed that TDF treatment significantly reduced the risk of HCC recurrence compared to ETV therapy.
CHINESE MEDICAL JOURNAL
(2022)
Article
Gastroenterology & Hepatology
Wei-Yu Kao, Elise Chia-Hui Tan, Hsin-Lun Lee, Yi-Hsiang Huang, Teh-Ia Huo, Chun-Chao Chang, Jeng-Fong Chiou, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
Summary: This study compared the prognoses of patients with HBV-related HCC after hepatectomy who received ETV or TDF treatment and found that both treatments showed similar health benefits in terms of tumor recurrence and overall survival.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Immunology
Hao Zheng, Zebin Zhu, Ning Wang, Jiwei Qin, Yafei Guo, Zhijun Xu, Xuefeng Li, Can Qi, Xiaodong Yuan, Wei Wu, Jizhou Wang, Lianxin Liu, Bjorn Nashan
Summary: This study evaluated the effect of entecavir combined with short-term HBIG in preventing HBV recurrence after liver transplant. The results showed that only 1 patient appeared positive for hepatitis B surface antigen at 2 months post-LT. The overall HBV recurrence rate was 1.8%. This indicates that entecavir combined with short-term HBIG has a good effect in preventing HBV reinfection post-LT.
TRANSPLANTATION PROCEEDINGS
(2023)
Article
Multidisciplinary Sciences
Te-Sheng Chang, Yao-Hsu Yang, Wei-Ming Chen, Chien-Heng Shen, Shui-Yi Tung, Chih-Wei Yen, Yung-Yu Hsieh, Chuan-Pin Lee, Meng-Ling Tsai, Chao-Hung Hung, Sheng-Nan Lu
Summary: It remains controversial whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are associated with different clinical outcomes for chronic hepatitis B (CHB). This study compared the long-term risk of ETV versus TDF on hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) in CHB patients, showing a comparable risk for both medications.
SCIENTIFIC REPORTS
(2021)
Article
Surgery
Linye He, Zijing Xia, Xiaoyun Zhang, Zhihui Li, Tianfu Wen, Chuan Li
Summary: This study found that HBV-related HCC patients treated with consistent TDF therapy had a significantly lower risk of tumor recurrence than those treated with ETV after curative treatment.
INTERNATIONAL JOURNAL OF SURGERY
(2023)
Review
Immunology
Silvia Martini, Francesco Tandoi, Renato Romagnoli, Mario Rizzetto
Summary: Hepatitis D, caused by the hepatitis D virus, is the most severe form of viral hepatitis in humans. Liver transplantation is currently the only therapeutic option for terminal HDV disease, but it is not accessible in poor countries. In high-income countries, hepatitis B virus vaccination has significantly reduced the prevalence of HDV infection, but there is still a demand for liver transplantation among aging cirrhotics who acquired hepatitis D decades ago.
Article
Medicine, General & Internal
Pengpeng Li, Yuanyuan Wang, Jian Yu, Judian Yu, Qifei Tao, Jinwei Zhang, Wan Yee Lau, Weiping Zhou, Gang Huang
Summary: This retrospective cohort study compared the recurrence-free survival and overall survival rates of patients with hepatitis B virus-related hepatocellular carcinoma who received either tenofovir disoproxil or entecavir as antiviral treatment. The study found that tenofovir disoproxil was associated with better long-term overall survival and recurrence-free survival rates compared to entecavir.
Article
Gastroenterology & Hepatology
Jihye Lim, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Summary: Real-world data suggests that TAF and TDF have comparable efficacies in treating CHB, with similar virological responses and ALT normalization, and no higher risk of HCC.
LIVER INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Satoru Hagiwara, Naoshi Nishida, Kazuomi Ueshima, Akihiro Yoshida, Yasunori Minami, Masatoshi Kudo
Summary: The study found that switching from ETV to TAF in patients with CHB showed similar efficacy in decreasing HBsAg levels and safety compared to continuous ETV treatment.
HEPATOLOGY RESEARCH
(2021)